查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715896

醣質學/糖生物學市場（按產品類型、應用和最終用戶）—2025-2030 年全球預測

Glycomics/Glycobiology Market by Product Type, Applications, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計醣質學/糖生物學市場規模到 2024 年將達到 15.4 億美元，到 2025 年將達到 17.6 億美元，複合年成長率為 16.46%，到 ​​2030 年將達到 38.4 億美元。

主要市場統計數據
基準年2024年 15.4億美元
預計2025年 17.6億美元
預測年份 2030 38.4億美元
複合年成長率（%） 16.46%

醣體學和糖生物學已成為生物醫學研究和創新的關鍵領域，為深入了解聚醣在各種生物過程中的結構和功能提供了基礎。尖端科技與方法的融合正在開啟疾病診斷和治療發展的新時代，從根本上改變科學家和決策者看待健康和疾病的方式。

蛋白質糖基化研究和聚醣分析的最新進展為發現新的生物標記、改善患者分層以及更深入地了解細胞訊號通路鋪平了道路。隨著這些領域的持續快速發展，結合化學、生物學和技術的多學科方法正在為影響臨床實踐和藥物創新的革命性突破奠定基礎。

改變醣質學/糖生物學市場

過去十年來，糖科學和糖生物學發生了重大變化。科學突破和技術進步重新定義了研究參數和市場動態。研究人員目前正在使用次世代定序儀、高通量篩檢和先進的建模平台來闡明複雜的聚醣結構及其生物學作用。

創新的診斷技術不僅加速了癌症和遺傳疾病的檢測，而且拓寬了感染疾病診斷的範圍，從而帶來更個人化的醫療保健解決方案。同時，基於糖的療法和藥物傳遞系統的快速發展為製藥和生物技術領域開闢了新的途徑，並鼓勵對研發進行大力投資。

此外，人工智慧和機器學習演算法與聚醣分析的結合簡化了數據處理並改善了預測結果，推動了整個行業向精準醫療的轉變。這種狀況反映了傳統方法的動態性質，傳統方法正迅速被敏捷的、技術主導的方法所取代，這些方法支撐了研究和臨床應用的模式轉移。

全面的細分洞察推動創新

醣質學市場的細分洞察揭示了複雜的分析層面，這對於理解產業趨勢和有希望的成長機會至關重要。依產品類型評估市場時，研究涵蓋酵素、儀器、套件和試劑/化學品。酵素分析深入糖苷酶-神經氨酸酶組合、糖基轉移酶-唾液酸轉移酶組合、蛋白質磺基轉移酶-硫酸酯酶組合等類別。這種細粒度的方法將有助於為每個酶亞組制定客製化策略。

儀器儀表發揮至關重要的作用，詳細評估包括陣列、層析法儀器、電泳儀器、HPLC管柱和質譜儀器。這些工具處於方法學進步的前沿，能夠實現高度準確的聚醣分析並促進複雜的生物技術應用。同樣，套件類別提供了各種技術工具的見解，例如聚醣檢測套件、聚醣富集試劑套件、聚醣標記試劑套件、聚醣精製套件、聚醣純化試劑套件、聚醣釋放試劑套件、聚醣樣品製備試劑套件和聚醣定序套件。這些解決方案均旨在提高聚醣分析的敏感度和特異性，支持多層次的診斷和治療研究方法。

此外，市場分析基於應用，重點是診斷和治療。在診斷方面，它強調了早期檢測和策略性介入的重要性，並分析了癌症檢測、遺傳疾病和感染疾病等應用。治療應用同樣強大，並在藥物傳輸系統、藥物開發和藥物發現的標題下進行進一步評估，每個都在解決各種臨床挑戰中發揮關鍵作用。

最終用戶細分透過考慮學術研究機構、受託研究機構、製藥和生物技術公司等不同營業單位，進一步細分市場格局。這種全面的細分評估有助於對各個市場促進因素、投資模式和未來成長軌跡有細緻的了解，使相關人員能夠有效地縮小研究重點並策略性地分配資源。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 個人化醫療需求的不斷成長加速了基於醣質學的診斷工具的開發
      • 需要基於聚醣的治療方法的慢性病盛行率不斷上升
    • 限制因素
      • 缺乏與醣質學研究相關的數據的整合和標準化
    • 機會
      • 質譜技術的不斷進步正在改善醣質學的分析和能力。
      • 增加全球醣質學研究和發展舉措的政府資助和夥伴關係
    • 任務
      • 高品質聚醣庫和試劑的供應有限
  • 市場區隔分析
    • 產品類型：由於其便利性和方便用戶使用性，套件的需求量很大
    • 應用：醣質學/糖生物學在診斷中的關鍵作用
    • 最終用戶：醣質學/糖生物學在製藥和生物技術公司中的廣泛應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章醣質學/糖生物學市場（依產品類型）

  • 酵素
    • 糖苷酶和神經氨酸酶
    • 糖基轉移酶和唾液酸轉移酶
    • 蛋白質磺基轉移酶和硫酸酯酶
  • 裝置
    • 大批
    • 層析法設備
    • 電泳設備
    • HPLC管柱
    • 質譜儀
  • 套件
    • 聚醣檢測試劑套件
    • 聚醣富集試劑套件
    • 聚醣標記試劑套件
    • 聚醣分析試劑套件
    • 聚醣精製套件
    • 聚醣釋放套件
    • 聚醣樣品製備套件
    • 聚醣定序套件
  • 試劑和化學品

第7章醣質學/糖生物學市場（按應用）

  • 診斷
    • 癌症檢測
    • 遺傳性疾病
    • 感染疾病
  • 治療
    • 藥物輸送系統
    • 藥物開發
    • 藥物研發

第 8 章醣質學/糖生物學市場（按最終用戶）

  • 學術研究所
  • 合約研究組織
  • 製藥和生物技術公司

9. 美洲醣質學/糖生物學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10. 亞太地區醣質學/糖生物學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

11. 歐洲、中東和非洲的醣質學/糖生物學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Agilent Technologies, Inc.
  • AMSBIO
  • Asparia Glycomics
  • Bio-Techne Corporation
  • Bruker Corporation
  • Chemily Glycoscience
  • Creative Diagnostics
  • FUJIFILM Wako Pure Chemical Corporation
  • Genos Glyco
  • Glycan Therapeutics
  • GlycoDiag
  • glyXera GmbH
  • ICE Spa
  • Lectenz Bio, Inc.
  • Ludger Ltd
  • Megazyme Ltd. by Neogen Corporation
  • Merck KGaA
  • New England Biolabs, Inc.
  • QIAGEN NV
  • RayBiotech, Inc.
  • Revvity, Inc.
  • SCIEX by Danaher Corporation
  • Shimadzu Corporation
  • Sumitomo Bakelite Co., Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Vector Laboratories, Inc.
  • Waters Corporation
  • Z Biotech, LLC
  • Zacharon Pharmaceuticals, Inc.
Product Code: MRR-3D2FD205BD43

The Glycomics/Glycobiology Market was valued at USD 1.54 billion in 2024 and is projected to grow to USD 1.76 billion in 2025, with a CAGR of 16.46%, reaching USD 3.84 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.54 billion
Estimated Year [2025] USD 1.76 billion
Forecast Year [2030] USD 3.84 billion
CAGR (%) 16.46%

Glycomics and glycobiology have emerged as pivotal fields within biomedical research and innovation, offering profound insights into the structure and function of carbohydrates in various biological processes. The integration of cutting-edge technologies and methodologies has ushered in a new era of disease diagnostics and therapeutic development, fundamentally altering how scientists and decision-makers perceive health and disease.

Recent advancements in protein glycosylation studies and carbohydrate profiling have paved the way for novel biomarker discoveries, improved patient stratification, and a deeper understanding of cellular signaling pathways. As these fields continue evolving rapidly, the interdisciplinary approach uniting chemistry, biology, and technology is setting the stage for transformative breakthroughs that impact clinical practice and pharmaceutical innovation.

Transformative Shifts in the Glycomics and Glycobiology Landscape

The last decade has witnessed transformative shifts in glycomics and glycobiology. Scientific breakthroughs, coupled with technological advancements, have redefined research parameters and market dynamics. Researchers now leverage next-generation sequencing, high-throughput screening, and sophisticated modeling platforms to demystify complex carbohydrate structures and their biological roles.

Innovative diagnostic techniques have not only accelerated the detection of cancer and genetic disorders but have also expanded the horizons for infectious disease diagnosis, leading to more personalized healthcare solutions. In parallel, the rapid development of glycan-based therapeutics and drug delivery systems has opened avenues for the pharmaceutical and biotechnology sectors, stimulating robust investments in research and development.

Furthermore, the integration of artificial intelligence and machine learning algorithms into glycan analytics has streamlined data processing and enhanced predictive outcomes, underscoring an industry-wide shift toward precision medicine. These milestones reflect the dynamic nature of the landscape, where traditional practices are rapidly being replaced by agile, technology-driven approaches that underline a paradigm shift in both research and clinical applications.

Comprehensive Segmentation Insights Driving Innovation

The segmentation insights in the glycomics market reveal intricate layers of analysis that are critical in understanding industry trends and promising growth opportunities. When evaluating the market based on product type, the study encompasses enzymes, instruments, kits, and reagents & chemicals. Enzyme analysis delves into categories such as glycosidases paired with neuramidases, glycosyltransferases together with sialytransferases, as well as protein sulfotransferases combined with sulfatases. This granular approach facilitates tailored strategy formulations for each enzymatic subgroup.

Instruments play a pivotal role, with detailed assessments extending to arrays, chromatography instruments, electrophoresis instruments, HPLC columns, and mass spectrometry instruments. These tools are at the forefront of methodological advancements, enabling highly accurate glycan profiling and facilitating complex biotechnological applications. Similarly, the kits category offers insights into a range of technical tools, including glycan detection kits, glycan enrichment kits, glycan labeling kits, glycan profiling kits, glycan purification kits, glycan releasing kits, glycan sample preparation kits, and glycan sequencing kits. Each of these solutions is designed to enhance sensitivity and specificity in glycan analysis, thus supporting a layered approach to diagnostics and therapeutic research.

Furthermore, the market is analyzed based on applications where the focus is placed on diagnostics and therapeutics. On the diagnostics front, the analysis covers applications in cancer detection, genetic disorders, and infectious diseases, highlighting the importance of early detection and strategic intervention. Therapeutic applications are equally robust, being further evaluated under drug delivery systems, drug development, and drug discovery, each playing a key role in addressing various clinical challenges.

The end-user segmentation further refines the market outlook by considering distinct entities such as academic research institutes, contract research organizations, and pharmaceutical & biotechnology companies. This comprehensive segmentation assessment facilitates a nuanced understanding of individual market drivers, investment patterns, and future growth trajectories, enabling stakeholders to effectively target their research priorities and allocate resources strategically.

Based on Product Type, market is studied across Enzymes, Instruments, Kits, and Reagents & Chemicals. The Enzymes is further studied across Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, and Protein Sulfotransferases & Sulfatases. The Instruments is further studied across Arrays, Chromatography Instruments, Electrophoresis Instruments, HPLC Columns, and Mass Spectrometry Instruments. The Kits is further studied across Glycan Detection Kits, Glycan Enrichment Kits, Glycan Labeling Kits, Glycan Profiling Kits, Glycan Purification Kits, Glycan Releasing Kits, Glycan Sample Preparation Kits, and Glycan Sequencing Kits.

Based on Applications, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Cancer Detection, Genetic Disorders, and Infectious Diseases. The Therapeutics is further studied across Drug Delivery Systems, Drug Development, and Drug Discovery.

Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.

Regional Dynamics Shaping the Global Glycomics Market

Regional insights indicate that market evolution is influenced by variations in research funding, technological adoption, and regulatory landscapes. In the Americas, well-established research infrastructures and high investments in biopharmaceutical research encourage significant progress, fostering a dynamic research environment autochthonous to groundbreaking diagnostic and therapeutic projects.

The region comprising Europe, the Middle East, and Africa exemplifies a balanced mix of robust academic research and industrial initiatives. Europe stands out with its advanced technological platforms and strategic alliances, while the Middle East and Africa showcase emerging markets keen on leveraging glycomics as a driver for future healthcare innovations.

Across the Asia-Pacific region, rapid technological advancements and expanding research capabilities contribute robustly to the overall market growth. Countries in this region are increasingly investing in research and clinical applications, thereby accelerating the adoption of novel glycomics technologies and solutions. These regional dynamics underscore the fact that global market trends are not homogenous but instead reflect a blend of local priorities, economic conditions, and infrastructural strengths, driving a complex yet promising global market landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Innovators and Industry Pioneers

Key company insights reveal that the competitive landscape is enriched by an array of leading innovators and technology pioneers who continue to redefine standards in glycomics and glycobiology. Firms such as Agilent Technologies, Inc. and AMSBIO are setting benchmarks with advanced instrumentation and high-quality reagents that enable precise and efficient glycan analysis. Emerging players like Asparia Glycomics and Bio-Techne Corporation have contributed innovative solutions that cater to specific needs in both research and clinical settings.

Other influential companies such as Bruker Corporation and Chemily Glycoscience have made significant strides in the development of state-of-the-art analytical instruments and diagnostic kits, forging new paths in glycomics technology. Creative Diagnostics, FUJIFILM Wako Pure Chemical Corporation, and Genos Glyco have played substantial roles in product diversification and technological refinement, thereby expanding the application horizons. Additionally, Glycan Therapeutics, GlycoDiag, and glyXera GmbH are notable for their contributions to therapeutic advancements, while ICE S.p.a., Lectenz Bio, Inc., and Ludger Ltd. are recognized for pioneering dedicated enzymatic and assay solutions.

The competitive ecosystem is further enriched by companies such as Megazyme Ltd. by Neogen Corporation, Merck KGaA, and New England Biolabs, Inc., which maintain high standards in research and product development. Key market players like QIAGEN N.V., RayBiotech, Inc., and Revvity, Inc. continue to bolster growth by providing integrated platforms that combine automation and precision. Industry leaders such as SCIEX by Danaher Corporation, Shimadzu Corporation, and Sumitomo Bakelite Co., Ltd. are relentlessly pushing the frontiers of technology. Lastly, Takara Bio Inc., Thermo Fisher Scientific Inc., Tokyo Chemical Industry Co., Ltd., Vector Laboratories, Inc., Waters Corporation, Z Biotech, LLC, and Zacharon Pharmaceuticals, Inc. complete this constellation of enterprises, collectively driving industry innovation and spearheading the evolution of market strategies.

The report delves into recent significant developments in the Glycomics/Glycobiology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AMSBIO, Asparia Glycomics, Bio-Techne Corporation, Bruker Corporation, Chemily Glycoscience, Creative Diagnostics, FUJIFILM Wako Pure Chemical Corporation, Genos Glyco, Glycan Therapeutics, GlycoDiag, glyXera GmbH, ICE S.p.a., Lectenz Bio, Inc., Ludger Ltd, Megazyme Ltd. by Neogen Corporation, Merck KGaA, New England Biolabs, Inc., QIAGEN N.V., RayBiotech, Inc., Revvity, Inc., SCIEX by Danaher Corporation, Shimadzu Corporation, Sumitomo Bakelite Co., Ltd., Takara Bio Inc., Thermo Fisher Scientific Inc., Tokyo Chemical Industry Co., Ltd., Vector Laboratories, Inc., Waters Corporation, Z Biotech, LLC, and Zacharon Pharmaceuticals, Inc.. Strategic Recommendations for Market Leadership

For industry leaders navigating the challenges of an evolving glycomics and glycobiology market, formulating strategic recommendations is essential. It is imperative to invest in advanced technologies and robust analytics that can capture and process the complex data derived from glycan structures. Using integrated, high-throughput platforms will not only enhance analytical precision but will also aid in reducing turnaround times for critical diagnostics and research initiatives.

Leaders should prioritize the development of strong collaborative networks with academic and research institutions, ensuring that cross-disciplinary efforts translate into breakthrough solutions in diagnostics and therapeutics. Furthermore, aligning with regulatory bodies to streamline approval processes and ensure adherence to quality standards is crucial for accelerating market entry and sustaining competitive advantage. Investment in workforce talent and continuous training further supports the adoption of next-generation technologies, enabling teams to harness cutting-edge methodologies effectively.

Another key approach involves fostering strategic partnerships with technology innovators and established market players. These collaborations can create synergies that drive advancements in product development and open new market avenues. Companies are advised to diversify their portfolios across various segments such as enzymes, instruments, and kits, ensuring that there is a robust foundation to support both diagnostic and therapeutic applications.

Simultaneously, leveraging regional strengths and tailoring strategies to local market dynamics will strengthen global outreach. Executives should carry out comprehensive market analyses that consider the distinctive research environments and regulatory landscapes across regions including the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Streamlined integration of research insights with market strategies will fortify the positioning of any enterprise poised to lead in this competitive domain.

Summarizing the Strategic Landscape of Glycomics

In summary, the dynamic landscape of glycomics and glycobiology presents an array of opportunities that mirror the complexity and potential of carbohydrate research. The transformative shifts, underpinned by technological advancements and rising market segmentation, showcase an industry in transition. Detailed insights into product types, application areas, and end-user dynamics highlight the multifaceted nature of this sector, reinforcing its relevance in both the academic and clinical realms.

Key takeaways emphasize the role of innovative diagnostics and therapeutic strategies, the importance of precision instrumentation, and the significant impact of market-specific segmentation. Furthermore, the regional variations and competitive landscape underscore a globally interconnected market that is ripe for innovation. As industry trends continue to morph and expand, the synthesis of technological advancements with strategic market positioning remains critical for differentiating and accelerating growth.

This comprehensive understanding not only provides a roadmap for navigating future challenges but also sets the stage for pioneering approaches that resonate with the evolving needs of patients, researchers, and industry stakeholders alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising need for personalized medicine amplifying glycomics-based diagnostic tools development
      • 5.1.1.2. Increasing prevalence of chronic diseases necessitating glycan-based therapeutic approaches
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of data integration and standardization associated with glycomics research
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in mass spectrometry enhancing glycomic profiling and capabilities
      • 5.1.3.2. Increasing government funding and partnerships for glycomics research and development initiatives globally
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of high-quality glycan libraries and reagents
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing need for kits due to their convenience and user-friendly nature
    • 5.2.2. Applications: Crucial role of glycomics/glycobiology in diagnostics
    • 5.2.3. End-User: Widespread application of glycomics/glycobiology in pharmaceutical & biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glycomics/Glycobiology Market, by Product Type

  • 6.1. Introduction
  • 6.2. Enzymes
    • 6.2.1. Glycosidases & Neuramidases
    • 6.2.2. Glycosyltransferases & Sialytransferases
    • 6.2.3. Protein Sulfotransferases & Sulfatases
  • 6.3. Instruments
    • 6.3.1. Arrays
    • 6.3.2. Chromatography Instruments
    • 6.3.3. Electrophoresis Instruments
    • 6.3.4. HPLC Columns
    • 6.3.5. Mass Spectrometry Instruments
  • 6.4. Kits
    • 6.4.1. Glycan Detection Kits
    • 6.4.2. Glycan Enrichment Kits
    • 6.4.3. Glycan Labeling Kits
    • 6.4.4. Glycan Profiling Kits
    • 6.4.5. Glycan Purification Kits
    • 6.4.6. Glycan Releasing Kits
    • 6.4.7. Glycan Sample Preparation Kits
    • 6.4.8. Glycan Sequencing Kits
  • 6.5. Reagents & Chemicals

7. Glycomics/Glycobiology Market, by Applications

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Cancer Detection
    • 7.2.2. Genetic Disorders
    • 7.2.3. Infectious Diseases
  • 7.3. Therapeutics
    • 7.3.1. Drug Delivery Systems
    • 7.3.2. Drug Development
    • 7.3.3. Drug Discovery

8. Glycomics/Glycobiology Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Glycomics/Glycobiology Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Glycomics/Glycobiology Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Glycomics/Glycobiology Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. OBI Pharma collaboration with GlyTech to expand GlycOBI enabling technologies and to advance glycan production in Japan
    • 12.3.2. Michael Smith Health Research BC partners with GlycoNet with investment of USD 2.3 million
    • 12.3.3. GlycoNet invests USD 12 million in Canadian glycomics research to tackle health and agriculture challenges
    • 12.3.4. UK Biotechnology and Biological Sciences Research Council(BBSRC) awarded GBP 1.1 million in funds to Queen Mary University of London and Imperial College London
    • 12.3.5. GlycoNet and CQDM's transformative partnership aims to enhance drug discovery and healthcare solutions in Canada
    • 12.3.6. UGA receives an NSF award worth USD 18 million to broaden access to glycoscience
    • 12.3.7. GlycoNet and NOVA FCT collaborate to drive innovations in glycomics and glycoscience
    • 12.3.8. ReNAgade Therapeutics strengthens merger with GanNA Bio paving new pathways in glycomics research
    • 12.3.9. DAZZEON JAPAN strategic partnership with Hoshi University to innovate gastric lesion treatments through research
    • 12.3.10. Vector Laboratories partners with Navinci Diagnostics to innovate spatial proteomics for advanced biomarker discovery in glycosylation detection
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. Revvity, Inc.
    • 12.4.2. Ludger Ltd
    • 12.4.3. Vector Laboratories, Inc.
    • 12.4.4. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. AMSBIO
  • 3. Asparia Glycomics
  • 4. Bio-Techne Corporation
  • 5. Bruker Corporation
  • 6. Chemily Glycoscience
  • 7. Creative Diagnostics
  • 8. FUJIFILM Wako Pure Chemical Corporation
  • 9. Genos Glyco
  • 10. Glycan Therapeutics
  • 11. GlycoDiag
  • 12. glyXera GmbH
  • 13. ICE S.p.a.
  • 14. Lectenz Bio, Inc.
  • 15. Ludger Ltd
  • 16. Megazyme Ltd. by Neogen Corporation
  • 17. Merck KGaA
  • 18. New England Biolabs, Inc.
  • 19. QIAGEN N.V.
  • 20. RayBiotech, Inc.
  • 21. Revvity, Inc.
  • 22. SCIEX by Danaher Corporation
  • 23. Shimadzu Corporation
  • 24. Sumitomo Bakelite Co., Ltd.
  • 25. Takara Bio Inc.
  • 26. Thermo Fisher Scientific Inc.
  • 27. Tokyo Chemical Industry Co., Ltd.
  • 28. Vector Laboratories, Inc.
  • 29. Waters Corporation
  • 30. Z Biotech, LLC
  • 31. Zacharon Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-CURRENCY
  • FIGURE 2. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-LANGUAGE
  • FIGURE 3. GLYCOMICS/GLYCOBIOLOGY MARKET RESEARCH PROCESS
  • FIGURE 4. GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 14. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 16. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 18. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 22. GLYCOMICS/GLYCOBIOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. GLYCOMICS/GLYCOBIOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLYCOMICS/GLYCOBIOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. GLYCOMICS/GLYCOBIOLOGY MARKET DYNAMICS
  • TABLE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSIDASES & NEURAMIDASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSYLTRANSFERASES & SIALYTRANSFERASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PROTEIN SULFOTRANSFERASES & SULFATASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ARRAYS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ELECTROPHORESIS INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY HPLC COLUMNS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN DETECTION KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN ENRICHMENT KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN LABELING KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN PROFILING KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN PURIFICATION KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN RELEASING KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN SAMPLE PREPARATION KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN SEQUENCING KITS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REAGENTS & CHEMICALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 44. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 46. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 47. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 48. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 49. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 50. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 51. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 52. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 53. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 54. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 55. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 56. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 57. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 58. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 59. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 60. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 61. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 62. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 63. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 64. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 65. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 66. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 67. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 68. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 69. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 70. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 71. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 72. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 73. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 74. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 75. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 76. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 77. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 78. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 79. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 80. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 81. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 82. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 83. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 84. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 85. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 86. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 87. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 88. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 89. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 90. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 91. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 92. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 93. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 94. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 95. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 96. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 97. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 98. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 99. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 100. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 101. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 102. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 103. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 104. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 105. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 106. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 107. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 108. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 109. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 110. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 111. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 112. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 113. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 114. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 115. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 116. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 117. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 118. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 119. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 120. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 121. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 122. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 123. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 124. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 125. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 126. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 127. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 128. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 129. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 130. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 131. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 132. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 133. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 134. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 135. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 136. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 137. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 138. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 139. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 140. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 141. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 142. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 143. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 144. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 145. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 146. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 147. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 148. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 149. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 150. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 151. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 152. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 153. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 154. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 155. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 156. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 157. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 158. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 159. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 160. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 161. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 162. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 163. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 164. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 165. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 166. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 167. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 168. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 169. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 170. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 171. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 172. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 173. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 174. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 175. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 176. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 177. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 178. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 179. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 180. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 181. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 182. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 183. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 184. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 186. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 187. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 188. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 189. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 190. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 191. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 192. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 193. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 194. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 195. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 196. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 197. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 198. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 199. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 200. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 210. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 211. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 212. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 213. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 214. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 215. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 216. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 217. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 218. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 219. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 220. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 221. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 222. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 223. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 224. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 225. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 226. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 227. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 228. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 229. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 230. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 231. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 232. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 233. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 234. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 235. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 236. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 237. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 238. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 239. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 240. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 241. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 242. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 243. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 244. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 245. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 246. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 247. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 248. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 249. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 250. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 251. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 252. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 253. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 254. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 255. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 256. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 257. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 258. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 259. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 260. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 261. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 262. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 263. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 264. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 265. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 266. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 267. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 268. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 269. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 270. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 271. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 272. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 273. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 274. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 275. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 276. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 277. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 278. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 279. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 280. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 281. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 282. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 283. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 284. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 285. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 286. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 287. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 288. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 289. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 290. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 291. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 292. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 293. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 294. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 295. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 296. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 297. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 298. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 299. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 300. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 301. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 302. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 303. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 304. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 305. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 306. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 307. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 308. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 309. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 310. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 311. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 312. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 313. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 314. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 315. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 316. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 317. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 318. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 319. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 320. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 321. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 322. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 323. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 324. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 325. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 326. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 327. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 328. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 329. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 330. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 331. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
  • TABLE 332. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
  • TABLE 333. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
  • TABLE 334. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
  • TABLE 335. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 336. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
  • TABLE 337. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 338. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 339.